Diagnosing chronic liver disease in primary care: developing a cost effective care pathway
Lead Research Organisation:
University of Nottingham
Department Name: School of Medicine
Abstract
Liver problems in people in the both the UK and internationally are becoming increasingly common. A number of experts in the field of liver disease study (hepatology) have called for early-identification of liver disease in the UK population, however there are large gaps in our knowledge about how to identify who will develop advanced liver disease (scarring, known as fibrosis) and in whom it will progress to cirrhosis and complications including liver failure and liver cancer.
Until recently the 'best' way of diagnosing liver scaring was by liver biopsy. An unpleasant procedure using a needle to obtain a sample of liver tissue. Over the past ten years there have been large advances in the development of non-invasive ways of measuring scarring such as blood tests and imaging. It has been suggested that these tests could be used to identify patients in primary care with liver disease earlier. We are currently unable to do this because of a number of factors, for example, we don't know how well these non-invasive tests work in the general population as they have been developed in selected hospital groups and we don't know how many people might be diagnosed with liver disease in order to plan appropriate follow-up care.
This fellowship proposal aims to address many of the missing elements in order to develop a cost effective diagnostic pathway for early-identification of liver disease in primary care in the UK. A number of projects are planned in order to develop the knowledge needed to do this.
Firstly, using a large routinely collected primary care data source (the Clinical Practice Research Datalink) I will estimate the impact of introducing different diagnostic tests for early-identification on patients and health service resources.
Secondly, using the same dataset I will compare the rate of liver complications (such as liver cancer) in the patients I have determined to have liver disease using non-invasive tests with the general population.
Thirdly, I will use a clinical study (the Nottingham Community (NCC) Study, also known as The Scarred Liver Project) to collect information about patients' quality of life. The NCC is offering high risk patients a specialist liver scan to diagnose scarring. I will measure these patients quality of life before their imaging and after to discover the impact having a diagnosis of liver disease has on them.
Together this new knowledge will allow me to estimate the impact of different strategies for early-identification on the frequency of liver disease diagnoses, rates of complications, impact on quality of life, and impact on behaviour. Together with information on the costs to the health service of different approaches to early-identification I will then determine the most efficient way to implement early identification of liver disease in primary care.
The results will guide the future clinical management of patients. I have already engaged with and have the support of a wide range of professionals who are involved in commissioning and developing clinical pathways in order to ensure the results of this work are implemented.
Until recently the 'best' way of diagnosing liver scaring was by liver biopsy. An unpleasant procedure using a needle to obtain a sample of liver tissue. Over the past ten years there have been large advances in the development of non-invasive ways of measuring scarring such as blood tests and imaging. It has been suggested that these tests could be used to identify patients in primary care with liver disease earlier. We are currently unable to do this because of a number of factors, for example, we don't know how well these non-invasive tests work in the general population as they have been developed in selected hospital groups and we don't know how many people might be diagnosed with liver disease in order to plan appropriate follow-up care.
This fellowship proposal aims to address many of the missing elements in order to develop a cost effective diagnostic pathway for early-identification of liver disease in primary care in the UK. A number of projects are planned in order to develop the knowledge needed to do this.
Firstly, using a large routinely collected primary care data source (the Clinical Practice Research Datalink) I will estimate the impact of introducing different diagnostic tests for early-identification on patients and health service resources.
Secondly, using the same dataset I will compare the rate of liver complications (such as liver cancer) in the patients I have determined to have liver disease using non-invasive tests with the general population.
Thirdly, I will use a clinical study (the Nottingham Community (NCC) Study, also known as The Scarred Liver Project) to collect information about patients' quality of life. The NCC is offering high risk patients a specialist liver scan to diagnose scarring. I will measure these patients quality of life before their imaging and after to discover the impact having a diagnosis of liver disease has on them.
Together this new knowledge will allow me to estimate the impact of different strategies for early-identification on the frequency of liver disease diagnoses, rates of complications, impact on quality of life, and impact on behaviour. Together with information on the costs to the health service of different approaches to early-identification I will then determine the most efficient way to implement early identification of liver disease in primary care.
The results will guide the future clinical management of patients. I have already engaged with and have the support of a wide range of professionals who are involved in commissioning and developing clinical pathways in order to ensure the results of this work are implemented.
Technical Summary
Rationale: CLD is one of the few diseases with an increasing incidence/prevalence both in the UK and internationally. Three independent UK reports have highlighted the need for the early detection of liver disease including the Chief Medical Officer report (2012), the All-Party Parliamentary Hepatology Group Inquiry and the Lancet commission in 2014.
Overall aim: To develop a cost-effective diagnostic strategy for CLD in primary care in the UK.
Methodology:
-The Clinical Practice Research Datalink (CPRD) will be used to phenotype CLD using easily available abnormal liver fibrosis/cirrhosis measures (AST/ALT ratio, APRI, FIB4, NAFLD Fibrosis Score) and to determine high risk target groups.
-Rates of CLD related complications over 5 and 10 years will be determined as relative and attributable risks associated with the non-invasive measure phenotyped CLD compared to the general population.
-Through primary data collection the Nottingham Community Cohort (NCC) Study will be used to collect and analyse health related quality of life data, pre- and post CLD diagnosis.
-Finally all components will be brought together in a cost-effectiveness assessment of different diagnostic strategies for CLD. The costs and benefits of alternative primary care pathways for identifying CLD against current practice will be modelled. A number of patient and societal effects are anticipated and data will be collected for analysis including: HRQoL, productivity, disease burden and health service costs and savings
Scientific and medical opportunities: This research will improve the applicability and reliability of clinical guidelines for the diagnosis of CLD in primary care. It will identify the most cost-effective strategy for integration into clinical care, with the intension of improving quality of care and outcomes for patients.
Overall aim: To develop a cost-effective diagnostic strategy for CLD in primary care in the UK.
Methodology:
-The Clinical Practice Research Datalink (CPRD) will be used to phenotype CLD using easily available abnormal liver fibrosis/cirrhosis measures (AST/ALT ratio, APRI, FIB4, NAFLD Fibrosis Score) and to determine high risk target groups.
-Rates of CLD related complications over 5 and 10 years will be determined as relative and attributable risks associated with the non-invasive measure phenotyped CLD compared to the general population.
-Through primary data collection the Nottingham Community Cohort (NCC) Study will be used to collect and analyse health related quality of life data, pre- and post CLD diagnosis.
-Finally all components will be brought together in a cost-effectiveness assessment of different diagnostic strategies for CLD. The costs and benefits of alternative primary care pathways for identifying CLD against current practice will be modelled. A number of patient and societal effects are anticipated and data will be collected for analysis including: HRQoL, productivity, disease burden and health service costs and savings
Scientific and medical opportunities: This research will improve the applicability and reliability of clinical guidelines for the diagnosis of CLD in primary care. It will identify the most cost-effective strategy for integration into clinical care, with the intension of improving quality of care and outcomes for patients.
Planned Impact
This fellowship proposal spans all three knowledge domains in the path to delivering impact: knowledge production, knowledge translation, knowledge exchange.
Given the aging population, diabetes and obesity epidemics and ongoing issues with alcohol consumption liver disease is a large and growing public health problem. Under the 2012 Health and Social Care Act, central government has given local authorities a core role in public health, with dedicated funding, supported by Public Health England. Additionally, to further support communities, Clinical Commissioning Groups (CCGS), made up of local general practitioners hold the purse strings and decide how to spend on healthcare. Not only will each of these stakeholders be impacted by this proposal directly through knowledge and actions on liver disease, but improving overall public health has significant economic impacts for industry and prosperity alongside reducing health inequalities
More specifically, this fellowship proposal has the potential to make a number of impacts:
-Policy-makers: Beyond the local and national UK interest in better understanding the use of non-invasive markers in the diagnosis of CLD this research is of interest globally. All Western countries are seeing an increase in CLD and none are currently in a position to take action due to this knowledge gap. It is essential that public health policies are driven by a sound evidence base in order to increase both the quality and effectiveness of services.
-Decision makers/budget holders: Parties commissioning healthcare services (e.g. CCGs) will benefit from local/national policy on liver disease care pathways in order to inform their spending and make cost-effective decisions.
-Commercial beneficiaries: Developers of existing or future liver fibrosis markers have the potential to be identified by this work.
-Third sector: A number of charities have an interest in liver health. For example, the British Liver Trust is a frontline organisation, communicating knowledge to the public. They provide information through a number of resources including their website which covers topics such as 'testing and screening' for liver disease. Providing the new information will strengthen their position in advocating for patients and assist with meeting their vision of 'best possible liver health for all'. This work will also inform the strategies of other groups e.g. British Society Gastroenterology, British Association for the Study of the Liver.
-Patients and the wider public: People at risk of liver disease have clear potential to benefit from this proposal through future screening for liver disease. This will in turn lead to their improved health and quality of life through a reduction in individual emergency admissions and complications of CLD.
-University of Nottingham: Building on existing skills and input from national/international experts, I will develop a research group with expertise in efficiently using routine data sets and health economics to answer applied health service research questions. My development with these skills and as an independent researcher will fill a current gap and build capacity to produce a team capable of being a resource for public and commercial researchers wishing to use this approach at other sites within the UK and Internationally. This area of work fits in with the goals of the Division of EPH to generate 'research which leads to positive changes in policy and practice across a range of clinical and public health research priority areas'.
All gains and impacts related to this proposal are foreseeable in the short to medium term (within 5 years of completion of the fellowship).
Given the aging population, diabetes and obesity epidemics and ongoing issues with alcohol consumption liver disease is a large and growing public health problem. Under the 2012 Health and Social Care Act, central government has given local authorities a core role in public health, with dedicated funding, supported by Public Health England. Additionally, to further support communities, Clinical Commissioning Groups (CCGS), made up of local general practitioners hold the purse strings and decide how to spend on healthcare. Not only will each of these stakeholders be impacted by this proposal directly through knowledge and actions on liver disease, but improving overall public health has significant economic impacts for industry and prosperity alongside reducing health inequalities
More specifically, this fellowship proposal has the potential to make a number of impacts:
-Policy-makers: Beyond the local and national UK interest in better understanding the use of non-invasive markers in the diagnosis of CLD this research is of interest globally. All Western countries are seeing an increase in CLD and none are currently in a position to take action due to this knowledge gap. It is essential that public health policies are driven by a sound evidence base in order to increase both the quality and effectiveness of services.
-Decision makers/budget holders: Parties commissioning healthcare services (e.g. CCGs) will benefit from local/national policy on liver disease care pathways in order to inform their spending and make cost-effective decisions.
-Commercial beneficiaries: Developers of existing or future liver fibrosis markers have the potential to be identified by this work.
-Third sector: A number of charities have an interest in liver health. For example, the British Liver Trust is a frontline organisation, communicating knowledge to the public. They provide information through a number of resources including their website which covers topics such as 'testing and screening' for liver disease. Providing the new information will strengthen their position in advocating for patients and assist with meeting their vision of 'best possible liver health for all'. This work will also inform the strategies of other groups e.g. British Society Gastroenterology, British Association for the Study of the Liver.
-Patients and the wider public: People at risk of liver disease have clear potential to benefit from this proposal through future screening for liver disease. This will in turn lead to their improved health and quality of life through a reduction in individual emergency admissions and complications of CLD.
-University of Nottingham: Building on existing skills and input from national/international experts, I will develop a research group with expertise in efficiently using routine data sets and health economics to answer applied health service research questions. My development with these skills and as an independent researcher will fill a current gap and build capacity to produce a team capable of being a resource for public and commercial researchers wishing to use this approach at other sites within the UK and Internationally. This area of work fits in with the goals of the Division of EPH to generate 'research which leads to positive changes in policy and practice across a range of clinical and public health research priority areas'.
All gains and impacts related to this proposal are foreseeable in the short to medium term (within 5 years of completion of the fellowship).
People |
ORCID iD |
Joanne Morling (Principal Investigator / Fellow) |
Publications
Al-Oraibi A
(2022)
Exploring the Psychological Impacts of COVID-19 Social Restrictions on International University Students: A Qualitative Study
in International Journal of Environmental Research and Public Health
Armitage RC
(2021)
The impact of COVID-19 on national screening programmes in England.
in Public health
Au-Yong I
(2022)
Chest Radiograph Scoring Alone or Combined with Other Risk Scores for Predicting Outcomes in COVID-19.
in Radiology
Au-Yong I
(2021)
Chest Radiograph Scoring Alone or Combined with Other Risk Scores for Predicting Outcomes in COVID-19: A UK Study.
in Radiology
Au-Yong I
(2022)
Chest Radiograph Scoring Alone or Combined with Other Risk Scores for Predicting Outcomes in COVID-19.
in Radiology
Bailey JA
(2021)
Quantitative FIT stratification is superior to NICE referral criteria NG12 in a high-risk colorectal cancer population.
in Techniques in coloproctology
Bailey JA
(2021)
GP access to FIT increases the proportion of colorectal cancers detected on urgent pathways in symptomatic patients in Nottingham.
in The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
Bennett L
(2022)
Health Technology Adoption in Liver Disease: Innovative Use of Data Science Solutions for Early Disease Detection
in Frontiers in Digital Health
Description | East Midlands Cancer Alliance |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Membership of a guideline committee |
Impact | Implementation of regional symptomatic FIT pathway/2WW for colorectal cancer. Adpation of pathways during covid-19. |
Description | Lancet Commission |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | National campaign highlighting best practice and communicating the need for policy action.New models of working are being shared and adopted e.g. the Scarred Liver Project. Training aspects adressed also. Ongoing through 2019 |
URL | http://www.thelancet.com/campaigns/liver |
Description | NASH consensus Roundtable (British Liver Trust) |
Geographic Reach | National |
Policy Influence Type | Contribution to a national consultation/review |
Impact | Standardisation of practice across the country - in progress |
Description | RCGP/BLT Commiissioning for liver disease in UK Primary care |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | Group formed to advise on best practice in commissioning for liver disease in UK priomary care. To include clinical pathways, commissioning models and education/training of workforce. First meeting 2018, ongoing in 2019 |
URL | http://www.rcgp.org.uk/clinical-and-research/a-to-z-clinical-resources/liver-disease.aspx |
Description | World Endoscopy Organisation - colorectal screening committee |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | Improvement oin practices for colorectal cancer detection both asymptomatic and symptomatic. |
Description | Age UK Derby and Derbyshire Derbyshire |
Amount | £8,000 (GBP) |
Organisation | Age UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2021 |
End | 12/2021 |
Description | Data analysis - Community liver disease pathway |
Amount | £96,000 (GBP) |
Organisation | Gilead Sciences, Inc. |
Sector | Private |
Country | United States |
Start | 12/2019 |
End | 09/2021 |
Description | Derbyshire covid-19 asymptomatic mass testing evaluation |
Amount | £25,992 (GBP) |
Organisation | Derbyshire County Council |
Sector | Public |
Country | United Kingdom |
Start | 01/2021 |
End | 12/2021 |
Description | Does knowledge of liver fibrosis affect high risk drinking behaviour (KLIFAD)? A feasibility randomised controlled trial. |
Amount | £248,543 (GBP) |
Funding ID | NIHR201146 |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 09/2020 |
End | 08/2022 |
Description | HEE/NIHR Doctoral Clinical and Practitioner Academic Fellowship (NIHR302872, for Nathan Davies) |
Amount | £36,093 (GBP) |
Funding ID | NIHR302872 |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 09/2023 |
End | 08/2026 |
Description | HEE/NIHR ICA Clinical Doctoral Fellowship (for Julia Knight) |
Amount | £500,000 (GBP) |
Funding ID | NIHR302137 |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 09/2022 |
End | 08/2025 |
Description | Knowledge Exchange funding - Community liver testing in underserved populations - a pilot study with the Nottinghamshire ICS |
Amount | £150,000 (GBP) |
Organisation | University of Nottingham |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2022 |
End | 07/2022 |
Description | NIHR CRN East Midlands - Underserved populations call |
Amount | £81,315 (GBP) |
Organisation | NIHR CRN Staff and Facilities Throughout the UK |
Sector | Public |
Country | United Kingdom |
Start | 07/2022 |
End | 03/2024 |
Description | NIHR Pre-Doctoral Local Authority Fellowship (for Joy Cotton) |
Amount | £73,275 (GBP) |
Funding ID | NIHR302086 |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 09/2021 |
End | 02/2024 |
Description | NIHR Pre-doctoral Fellowship |
Amount | £124,151 (GBP) |
Funding ID | NIHR301989 |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 09/2021 |
End | 08/2023 |
Description | NIHR Research Partnerships - Liver Disease |
Amount | £98,663 (GBP) |
Funding ID | NIHR155468 |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 02/2023 |
End | 01/2024 |
Description | NIHR RfPB [NIHR204124] |
Amount | £147,831 (GBP) |
Funding ID | NIHR204124 |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 03/2023 |
End | 02/2025 |
Description | NIHR School for Primary Care Research FR3-IV |
Amount | £78,101 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 01/2022 |
End | 06/2022 |
Description | Nottingham Hospitals Charity small value award |
Amount | £1,000 (GBP) |
Organisation | Nottingham Hospitals Charity |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2018 |
End | 09/2019 |
Description | PHIRST |
Amount | £2,500,000 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 03/2022 |
End | 02/2027 |
Description | Phase 4 Project NIHR CLAHRC East Midlands |
Amount | £18,417 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 09/2018 |
End | 03/2019 |
Description | QR Dunning: Covid in students - epidemiology theme |
Amount | £21,025 (GBP) |
Organisation | University of Nottingham |
Sector | Academic/University |
Country | United Kingdom |
Start | 12/2020 |
End | 03/2021 |
Description | Denmark - Liver disease routine data collaboration |
Organisation | Aarhus University |
Country | Denmark |
Sector | Academic/University |
PI Contribution | Using routine data for liver disease epidemiology. Collaborating on UK data - CPRD and Dannish data |
Collaborator Contribution | Access to Danish data Financial contribution to purchase of UK data Part access to a clinical post doc to support work |
Impact | Papers in draft Supporting data for grant applications |
Start Year | 2018 |
Description | Lancet Commision on Liver Disease |
Organisation | The Lancet |
Country | United Kingdom |
Sector | Private |
PI Contribution | Member of the commision. Ideas exchange Advocacy Publications |
Collaborator Contribution | Member of the commision. Ideas exchange Advocacy Publications |
Impact | Publication: 2018. Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK. The Lancet. Williams R, Alexander G, Aspinall R, Batterham R, Bhala N, Bosanquet N, Severi K, Burton A, Burton R, Cramp M, Day N, Dhawan A, Dillon J, Drummond C, Dyson J, Ferguson J, Foster G, Gilmore I, Greenberg J, Henn C, Hudson M, Jarvis H, Kelly D, Mann J, McDougall N, McKee M, Moriarty K, Morling J, Newsome P, O'Grady J, Rolfe L, Rice P, Rutter H, Sheron N, Thorburn D, Verne J, Vohra J, Wass J, Yeoman A |
Start Year | 2018 |
Description | UK Biobank |
Organisation | Glasgow Caledonian University |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Public health liver disease expertise Large data analysis expertise Mentorship |
Collaborator Contribution | Access to UKB data Analytic time and paper writing time |
Impact | Innes H#, Morling JR#, Aspinall EA, Goldberg DJ, Hutchinson SJ*, Guha IN* Late diagnosis of chronic liver disease in a community cohort (UK Biobank): determinants and impact on subsequent survival. Public Health 2020; in press Innes H . Morling JR et al Genome-wide Association Study for Alcohol-related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1 Gastroenterology 2020; |
Start Year | 2018 |
Description | Fellowship PPI support group |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Study participants or study members |
Results and Impact | Met with the 6 members of my PPI advisory team to discuss the output of the quality of life research undertaken and the proposed manuscript. Explored ideas interpreting the findings. |
Year(s) Of Engagement Activity | 2019 |
Description | Housing associateion PPI |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | Supporting tennants in social housing to understand about research |
Year(s) Of Engagement Activity | 2023 |
Description | KCL special interest group talk |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Professional Practitioners |
Results and Impact | Invited to speak to the Hepatology group at King's College London on the topic of screeening for liver disease in primary care. Aprox 25 attendees. Multiple contacts as a result of the event about a) potential future research collaborations b) practical support in getting clinical pathways implemented in their region. |
Year(s) Of Engagement Activity | 2017 |
Description | Knowledge exchange with Lincoln NHS Trust |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Sharing understanding of the Nottingham Liver pathway with Lincolnshire colleagues |
Year(s) Of Engagement Activity | 2022 |
Description | Lancet Liver commission V launch |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | Presentation at Lancet V launch to 80 people. Involvement of Adrian Chiles triggered media interest |
Year(s) Of Engagement Activity | 2018 |
Description | Lancet commission IV launch event |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Launch of the IV issue of the Lancet Commission into Liver Disease in the UK. I was an invited speaker on the topc of early diagnostic pathways in primary care. The event was attended by approximately 100 people, predominently clinicians and academics in the field but also representatives of RCGP, charities (British Liver Trust), AHPs and patients. A full afternoon of discussion on actions needed to take the agenda forward and to realise impact.As a result I was invited to join the Commission and a number of further research opportunities have been highlighted. Addiionally there has been ongoing interest from other regions of the UK outsiode of my own for supporting in implementing a pathway similar to our own. |
Year(s) Of Engagement Activity | 2018 |
URL | http://www.thelancet.com/campaigns/liver |
Description | Lancet liver launch VI |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Other audiences |
Results and Impact | Discussion event to highlight the state of liver disease diagnosis and management in the UK. Wide range of participants ~60 from a range of backgrounds bringing together experiences and ideas. |
Year(s) Of Engagement Activity | 2020 |
Description | PHIRST PPI |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | Ongoing PPI initiative to share learning around public health research based within the NIHR PHIRST-LIGHT |
Year(s) Of Engagement Activity | 2022,2023 |
URL | https://phirst.nihr.ac.uk/public-partnerships/ |
Description | SLP Shared learning day |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Multi stakeholder event to share learning from liver project |
Year(s) Of Engagement Activity | 2022 |
Description | School visit (NUAST) |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | Face mask research sharing |
Year(s) Of Engagement Activity | 2022 |
Description | Wellbeing in chronic liver disease: 3CN study workshop |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Study participants or study members |
Results and Impact | led a workshop exploring the delivery of services for chronic liver disease in order to support diagnosis and wellbeing. A mixture of presentations, small group discussions and brainstorming new ideas. Will provide valuable PPI insight or future applications |
Year(s) Of Engagement Activity | 2019 |